PMC:7594251 / 129329-132613
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T136 | 1294-1296 | Body_part | denotes | CS | http://purl.org/sig/ont/fma/fma284995 |
T137 | 2001-2008 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T138 | 2239-2243 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
T139 | 2301-2311 | Body_part | denotes | cell parts | http://purl.org/sig/ont/fma/fma78563 |
T140 | 2301-2305 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
T141 | 2432-2439 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T142 | 2508-2515 | Body_part | denotes | Protein | http://purl.org/sig/ont/fma/fma67257 |
T143 | 2593-2601 | Body_part | denotes | proteins | http://purl.org/sig/ont/fma/fma67257 |
T144 | 2864-2871 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T49 | 2301-2311 | Body_part | denotes | cell parts | http://purl.obolibrary.org/obo/UBERON_0000470 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T144 | 1077-1080 | Disease | denotes | MDD | http://purl.obolibrary.org/obo/MONDO_0012048|http://purl.obolibrary.org/obo/MONDO_0016217 |
T146 | 2010-2013 | Disease | denotes | STD | http://purl.obolibrary.org/obo/MONDO_0021681 |
T147 | 2809-2812 | Disease | denotes | HTS | http://purl.obolibrary.org/obo/MONDO_0011549 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T261 | 450-458 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | labeling |
T262 | 697-698 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T263 | 1594-1595 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T264 | 2029-2030 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T265 | 2239-2243 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
T266 | 2283-2288 | http://purl.obolibrary.org/obo/CLO_0009985 | denotes | focus |
T267 | 2301-2305 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
T268 | 2322-2330 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | labeling |
T269 | 2847-2852 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
T270 | 2912-2913 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T271 | 2935-2936 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T272 | 2962-2963 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T273 | 3025-3026 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T49784 | 370-376 | Chemical | denotes | nuclei | http://purl.obolibrary.org/obo/CHEBI_33252 |
T78546 | 388-390 | Chemical | denotes | 1H | http://purl.obolibrary.org/obo/CHEBI_49637 |
T55022 | 521-530 | Chemical | denotes | molecules | http://purl.obolibrary.org/obo/CHEBI_25367 |
T52980 | 578-584 | Chemical | denotes | nuclei | http://purl.obolibrary.org/obo/CHEBI_33252 |
T56383 | 1077-1080 | Chemical | denotes | MDD | http://purl.obolibrary.org/obo/CHEBI_566274 |
T21913 | 1294-1296 | Chemical | denotes | CS | http://purl.obolibrary.org/obo/CHEBI_73462 |
T84653 | 1670-1677 | Chemical | denotes | ligands | http://purl.obolibrary.org/obo/CHEBI_52214 |
T60113 | 1850-1856 | Chemical | denotes | ligand | http://purl.obolibrary.org/obo/CHEBI_52214 |
T79064 | 1991-1997 | Chemical | denotes | ligand | http://purl.obolibrary.org/obo/CHEBI_52214 |
T3417 | 2001-2008 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T86859 | 2104-2110 | Chemical | denotes | ligand | http://purl.obolibrary.org/obo/CHEBI_52214 |
T53221 | 2136-2143 | Chemical | denotes | ligands | http://purl.obolibrary.org/obo/CHEBI_52214 |
T59728 | 2432-2439 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T89255 | 2440-2444 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T90308 | 2493-2497 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T26569 | 2508-2515 | Chemical | denotes | Protein | http://purl.obolibrary.org/obo/CHEBI_16541 |
T60248 | 2593-2601 | Chemical | denotes | proteins | http://purl.obolibrary.org/obo/CHEBI_36080 |
T69582 | 2625-2629 | Chemical | denotes | ions | http://purl.obolibrary.org/obo/CHEBI_24870 |
T8333 | 2712-2717 | Chemical | denotes | atoms | http://purl.obolibrary.org/obo/CHEBI_33250 |
T65120 | 2853-2855 | Chemical | denotes | La | http://purl.obolibrary.org/obo/CHEBI_33336 |
T78430 | 2856-2863 | Chemical | denotes | antigen | http://purl.obolibrary.org/obo/CHEBI_59132 |
T1428 | 2864-2871 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T14147 | 2914-2931 | Chemical | denotes | chemical compound | http://purl.obolibrary.org/obo/CHEBI_37577 |
T89705 | 3206-3213 | Chemical | denotes | ligands | http://purl.obolibrary.org/obo/CHEBI_52214 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
2421 | 1294-1296 | Gene | denotes | CS | Gene:1431 |
2422 | 3107-3111 | Gene | denotes | spin | Gene:10927 |
2423 | 630-634 | Gene | denotes | spin | Gene:10927 |
2424 | 2971-2975 | Gene | denotes | pill | Gene:8319132 |
2425 | 186-190 | Gene | denotes | High | Gene:104137 |
2426 | 1805-1808 | Species | denotes | SAR | Tax:2698737 |
2427 | 2847-2852 | Species | denotes | human | Tax:9606 |
2428 | 282-284 | Chemical | denotes | 2D | |
2429 | 303-305 | Chemical | denotes | 2D | |
2430 | 388-390 | Chemical | denotes | 1H | |
2431 | 1635-1639 | Chemical | denotes | FBDD | |
2432 | 2619-2624 | Chemical | denotes | metal | MESH:D008670 |
2433 | 1077-1080 | Disease | denotes | MDD | MESH:D003865 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T61 | 2185-2193 | http://purl.obolibrary.org/obo/GO_0015297 | denotes | exchange |
T62 | 2834-2843 | http://purl.obolibrary.org/obo/GO_0009058 | denotes | synthesis |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T906 | 0-90 | Sentence | denotes | Table 3 Advantages and limitations of different NMR techniques developed in recent years. |
T907 | 91-131 | Sentence | denotes | NMR Technique Advantages Disadvantages |
T908 | 132-289 | Sentence | denotes | 1D-NMR Ability to identify simple chemical compounds.High quality resolution and sensitivity for many 1D experiments.Less time consuming compared to 2D NMR. |
T909 | 291-484 | Sentence | denotes | Compared to 2D NMR less details can be obtained for more complex molecules.For nuclei other than 1H and 19F, relative sensitivity is fairly low—requires extra labeling to obtain better spectra. |
T910 | 485-665 | Sentence | denotes | 2D NMR Ability to identify complex molecules and observe different interactions between the nuclei, e.g., correlations between all spins in one spin system using TOCSY experiment. |
T911 | 667-727 | Sentence | denotes | Requires long times to obtain a proper spectra (up to days). |
T912 | 728-788 | Sentence | denotes | Ultrafast 2D NMR Greatly reduces time to obtain 2D spectra. |
T913 | 790-810 | Sentence | denotes | Reduced sensitivity. |
T914 | 811-866 | Sentence | denotes | SOFAST Significantly reduces acquisition time of HMQC. |
T915 | 868-893 | Sentence | denotes | Relatively low resolution |
T916 | 894-973 | Sentence | denotes | NUS Lowers the time of measurement while keeping the same level of resolution. |
T917 | 975-1076 | Sentence | denotes | Requires use of reconstruction algorithms since missing data points can lead to artifacts in spectra. |
T918 | 1077-1207 | Sentence | denotes | MDD Multidimensional data are “broken” to one dimensional, which are easier to analyze.Ability to resolve overlapping resonances. |
T919 | 1210-1293 | Sentence | denotes | Data must be (approximately) symmetrical (Lorentzian shape) to obtain good spectra. |
T920 | 1294-1334 | Sentence | denotes | CS Good reconstruction of weaker peaks. |
T921 | 1336-1393 | Sentence | denotes | Large computational costs, low performance on noisy data. |
T922 | 1394-1445 | Sentence | denotes | MAX ENT Significant reduction in acquisition time. |
T923 | 1447-1534 | Sentence | denotes | Nominally Lorentzian peak shapes may be distorted, and peak intensities may be altered. |
T924 | 1535-1583 | Sentence | denotes | IST Greatly reduced time to obtain NMR spectra. |
T925 | 1585-1634 | Sentence | denotes | Requires a grid of uniformly sampled data points. |
T926 | 1635-1741 | Sentence | denotes | FBDD Often makes stronger binding ligands from weakly binding fragments.Less time and resource intensive. |
T927 | 1743-1804 | Sentence | denotes | Can be used only for small fragments of compound of interest. |
T928 | 1805-1857 | Sentence | denotes | SAR Direct observation of target binding to ligand. |
T929 | 1858-1904 | Sentence | denotes | Several types of NMR experiments are possible. |
T930 | 1906-2009 | Sentence | denotes | Inability to distinguish binding modes, difficult to gage the “true” binding site of ligand to protein. |
T931 | 2010-2119 | Sentence | denotes | STD Only requires a small amount of sample.Highly reproducible.Allows direct observations of ligand binding. |
T932 | 2121-2195 | Sentence | denotes | Only works for ligands with low binding affinity (fast chemical exchange). |
T933 | 2196-2235 | Sentence | denotes | Inability to distinguish binding modes. |
T934 | 2236-2312 | Sentence | denotes | In cell NMR In vivo studies are possible, can focus on specific cell parts. |
T935 | 2314-2358 | Sentence | denotes | Special labeling techniques may be required. |
T936 | 2359-2404 | Sentence | denotes | Spectra may be more challenging to interpret. |
T937 | 2405-2574 | Sentence | denotes | In silico + NMR Can model protein drug interactions, helps speed up and reduce cost of drug delivery Protein models need to be validated through experimental approach. |
T938 | 2575-2718 | Sentence | denotes | PNMR Can observe proteins interacting with metal ions, long observation distance (10-25 angstroms) between paramagnetic left and nearby atoms. |
T939 | 2720-2761 | Sentence | denotes | Paramagnetic left required in the system. |
T940 | 2762-2872 | Sentence | denotes | ALARM NMR Elimination of false positives from HTS methods It requires synthesis of human La antigen protein. |
T941 | 2873-3036 | Sentence | denotes | ssNMR Enables the characterization of a chemical compound in a solid-state form such as a tablet/pill.Provides insight into the physical properties of a compound. |
T942 | 3038-3125 | Sentence | denotes | Significant broadening of the spectral lineshapes due to anisotropic spin interactions. |
T943 | 3126-3214 | Sentence | denotes | Relaxation editing Noticeable difference in spectra of binding and non-binding ligands. |
T944 | 3216-3284 | Sentence | denotes | Sets the lower limit of time for which experiments can be performed. |